The Down Under medical community is excited with the emergence of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing impressive results in clinical trials for managing obesity. This medication https://bookmarklinx.com/story21827676/retatrutide-australia-a-potential-hope-for-weight-management